Runbo Zhong

Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC

Tianqing Chu, Runbo Zhong, Hua Zhong et al. · Journal of Thoracic Oncology · 2021 · 216 citations · Full text

Phase 1B, Advanced Nsclc, Sintilimab Plus Anlotinib +6

Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy

Jun Lü, Hua Zhong, Tianqing Chu et al. · European Respiratory Journal · 2018 · 94 citations

Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer

Runbo Zhong, Jiajun Teng, Baohui Han et al. · Cancer Immunology Immunotherapy · 2011 · 84 citations · Full text

Cancer Immunosurveillance, Medicine, Immunology +10

Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies

Jie Qian, Wei Nie, Jun Lü et al. · International Journal of Cancer · 2019 · 62 citations · Full text

MMP9 activation triggered by epidermal growth factor induced FoxO1 nuclear exclusion in non-small cell lung cancer

Jun Pei, Yuqing Lou, Runbo Zhong et al. · Tumor Biology · 2014 · 59 citations